$ AAPL

$ ABBV

$ ABNB

$ ACGL

$ ADI

$ ADM

$ ADP

$ ADSK

$ AEE

$ AEP

$ AES

$ AFL

$ AIG

$ AIZ

$ AJG

$ AKAM

$ ALB

$ ALGN

$ ALL

$ AMAT

$ AMCR

$ AMD

$ AME

$ AMGN

$ AMP

$ AMT

$ AMZN

$ ANET

$ AOS

$ APA

$ APD

$ APO

$ APTV

$ ARE

$ ATO

$ AVB

$ AWK

$ AXON

$ BA

$ BALL

$ BAX

$ BBY

$ BDX

$ BEN

$ BG

$ BIIB

$ BKNG

$ BLDR

$ BMY

$ BR

$ BRO

$ BXP

$ CAG

$ CAH

$ CARR

$ CAT

$ CBOE

$ CBRE

$ CCL

$ CDNS

$ CDW

$ CEG

$ CF

$ CHD

$ CHRW

$ CI

$ CINF

$ CL

$ CLX

$ CMCSA

$ CMG

$ CMI

$ CMS

$ COIN

$ COO

$ COP

$ COR

$ CPAY

$ CPT

$ CRL

$ CRWD

$ CSCO

$ CTRA

$ CTSH

$ CTVA

$ CVS

$ CVX

$ CZR

$ DAL

$ DASH

$ DAY

$ DD

$ DDOG

$ DE

$ DELL

$ DG

$ DGX

$ DIS

$ DOC

DexCom beat Q2 revenue and EPS expectations with strong sensor growth, but margin pressures and declining hardware sales temper the outlook despite raised FY2025 guidance.

# DexCom Delivers Strong Q2 FY2025 Revenue Beat, But Margin Pressures Temper Outlook

---

## Executive Summary

- **DexCom (DXCM) posted a robust Q2 FY2025, with revenue of $1.157B and non-GAAP EPS of $0.48, both exceeding consensus and internal guidance.** The top-line beat was driven by continued strength in the sensor business (up 18% YoY), offsetting a sharp 31% YoY decline in hardware revenue.
- **Earnings quality was mixed:** While operating margins improved due to disciplined SG&A control, gross margins compressed by 340bps YoY (non-GAAP) to 60.1%, reflecting higher logistics costs and recall-related expenses.
- **Management struck a bullish tone on growth,** citing record new customer starts, a 16% YoY increase in international revenue, and progress in non-insulin patient segments. However, they acknowledged near-term margin headwinds from supply chain and recall issues.
- **Guidance was raised:** FY2025 revenue is now expected in the $4.6–$4.625B range, reflecting confidence in continued top-line momentum. However, management’s margin outlook remains cautious, diverging from some of the more optimistic analyst targets.
- **Risks include ongoing margin pressure, a high debt-to-equity ratio (1.14), and competitive threats from emerging therapies.** Upside potential remains in the expanding sensor business and international markets. Near-term, the market may be overvaluing headline growth while underappreciating margin and hardware revenue risks. **Catalyst watch:** Margin stabilization and competitive developments in diabetes therapies.

---

## Performance Snapshot

| Metric                | Reported   | Consensus | Surprise | YoY Change |
|-----------------------|------------|-----------|----------|------------|
| Revenue               | $1.157B    | $1.13B    | +2.4%    | +11%       |
| GAAP EPS              | $0.45      | $0.41     | +$0.04   | +15%       |
| Non-GAAP EPS          | $0.48      | $0.44     | +$0.04   | +14%       |
| Sensor Revenue Growth | +18% YoY   |           |          |            |
| Hardware Revenue      | -31% YoY   |           |          |            |
| International Revenue | +16% YoY   |           |          |            |
| Non-GAAP Gross Margin | 60.1%      | 63.5%*    | -3.4pp   | -3.4pp     |
| GAAP Gross Margin     | 59.5%      | 62.4%*    | -2.9pp   | -2.9pp     |
| Operating Margin (GAAP)| 18.4%     |           |          | +1.2pp     |
| Debt-to-Equity Ratio  | 1.14       |           |          | +0.10      |

*Prior year

---

## Earnings Quality

DexCom’s Q2 FY2025 revenue mix was **heavily weighted toward sensors**, which delivered 18% YoY growth and offset a significant 31% YoY decline in hardware revenue. While top-line growth was strong, **gross margin compression (down 340bps YoY non-GAAP)** was notable, driven by expedited shipping and recall costs. However, **tight SG&A controls** allowed operating margins to improve YoY, partially mitigating the impact of higher COGS. The divergence between robust sales growth and pressured profitability is a key theme this quarter.

---

## Management Commentary & Guidance

Management’s tone on the call was **confident and growth-oriented**, highlighting record new customer starts, international expansion (+16% YoY), and traction in non-insulin patient segments. However, they were **explicitly cautious on near-term margin recovery**, citing ongoing supply chain and recall-related headwinds. **FY2025 revenue guidance was raised to $4.6–$4.625B**, reflecting continued confidence in demand, but margin guidance was left intentionally conservative, with management emphasizing a focus on long-term profitability over short-term gains.

---

## Key Risks

- **Margin Pressures:** Elevated logistics and recall costs may persist into H2 FY2025, weighing on gross margins.
- **Competitive Threats:** Emerging therapies (e.g., from Sana Biotechnology) could disrupt DexCom’s core market.
- **Balance Sheet:** A **debt-to-equity ratio of 1.14** is higher than peers, potentially limiting financial flexibility.
- **Hardware Revenue Decline:** The 31% YoY drop in hardware sales could signal product cycle or competitive issues.

---

## Expected Market Reaction

Analysts and investors are likely to **react positively to the revenue and EPS beat and the raised guidance**, but the **margin compression and hardware revenue decline may temper enthusiasm**. Options market activity in the $75–$85 strike range suggests some investors are positioning for downside volatility. The stock is expected to trade modestly higher, but with a cautious undertone.

---

## Final Takeaway

DexCom delivered a **strong top-line quarter** with clear momentum in its sensor and international businesses, but **margin pressures and hardware revenue declines are underappreciated risks**. The market may be **overvaluing headline growth** while not fully pricing in profitability headwinds and competitive threats. 

**Upcoming catalysts:**  
1. Margin stabilization in H2 FY2025  
2. Competitive updates in diabetes therapy landscape

Overall, this was a **solid but not flawless quarter**—investors should watch for margin recovery and competitive developments as key drivers of future performance.

DexCom (DXCM): Growth Outpaces Margin Concerns

DexCom’s strong sensor-driven revenue growth is offset by persistent margin pressures from supply chain and inventory challenges, leading to a cautious near-term earnings outlook.

# DexCom, Inc.: Sensor Momentum vs. Margin Headwinds—A Forward-Looking Earnings Outlook

## Executive Summary

We maintain a **Neutral** outlook on DexCom, Inc. (NASDAQ: DXCM) for the upcoming quarter. While **sensor-driven revenue growth remains robust (+17% YoY)** and new patient starts are at record highs, **GAAP gross margin compression to 56.9% (down 410 bps YoY)** signals persistent cost and supply chain pressures. The market may be underestimating the near-term impact of **inventory and supply chain inefficiencies**, as evidenced by a $28.2M charge in Q1 and management’s cautious tone. A key risk is the potential for further margin erosion if operational improvements lag expectations, despite strong top-line momentum.

## Recent Trends Signal What’s Next

DexCom’s last two quarters highlight a clear divergence: **top-line growth is accelerating, but profitability is under pressure**. Q1 2024 revenue reached **$1.036B (+12% YoY)**, driven by U.S. market strength (+15% YoY) and sensor adoption, while hardware revenue declined sharply (–42% YoY). However, **GAAP gross margin fell to 56.9% from 61.0% YoY**, reflecting supply chain and inventory challenges.

### Revenue, Margin, and EPS Trend Table

| Quarter      | Revenue ($B) | Gross Margin (%) | Operating Margin (%) | EPS ($) |
|--------------|--------------|------------------|----------------------|---------|
| Q2 2023      | 0.910        | 61.0             | 19.2                 | 0.28    |
| Q3 2023      | 0.950        | 60.2             | 18.5                 | 0.27    |
| Q4 2023      | 1.010        | 58.7             | 17.0                 | 0.25    |
| Q1 2024      | 1.036        | 56.9             | 15.8                 | 0.23    |

**Trend:** Revenue is steadily rising, but both gross and operating margins are declining, with EPS following suit. This pattern suggests that unless cost controls improve, margin pressure will persist into the next quarter.

## Management’s Forward Tone and Positioning

Management’s recent commentary reflects **measured optimism**. In the Q1 2024 call, they stated, “We continue to see strong demand and record new patient starts, particularly in the U.S.,” but also cautioned, “Short-term margin pressures remain manageable as we address supply chain challenges.” The decision to initiate a **$750M share repurchase** signals confidence in long-term cash flows, but the lack of upward revision to full-year guidance after a strong Q1 indicates a **prudent, risk-aware stance**.

Compared to prior quarters, the tone has shifted from “aggressive expansion” to “operational discipline,” with a greater focus on cost management and inventory normalization. This suggests management is prioritizing **stability and execution** over near-term upside.

## KPI Trends & Upcoming Quarter Drivers

The most relevant KPIs for the next quarter are:

- **Sensor Revenue Growth:** +17% YoY in Q1, expected to remain the primary growth engine.
- **Net New Customers:** 500,000–600,000 projected for 2024, with record new patient starts in the Type 2 non-insulin segment.
- **Inventory Charges:** $28.2M in Q1, a key indicator of ongoing supply chain and working capital challenges.

### KPI Movement Table

| KPI                   | Q1 2023 | Q4 2023 | Q1 2024 | YoY Change | QoQ Change |
|-----------------------|---------|---------|---------|------------|------------|
| Sensor Revenue ($M)   | 720     | 850     | 842     | +17%       | –1%        |
| Net New Customers     | 120k    | 150k    | 155k    | +29%       | +3%        |
| Inventory Charges ($M)| 12.5    | 18.0    | 28.2    | +126%      | +57%       |

**Implication:** Sustained sensor revenue and customer growth will support top-line results, but rising inventory charges could further pressure margins and cash flow if not contained.

## Missed by the Street

A subtle but important signal is management’s **explicit reference to “manageable” margin pressures** and the need for “additional working capital adjustments.” This language, buried in the Q1 2024 10-Q, suggests that **operational costs may be stickier than consensus expects**. Additionally, the **FDA warning letter**—while not yet material to revenue—could introduce unforeseen regulatory costs or delays if not resolved promptly.

## Scenarios for the Upcoming Quarter

### Scenario Table

| Scenario | Key Assumptions                                              | Revenue ($B) | EPS ($) | GAAP Gross Margin (%) |
|----------|-------------------------------------------------------------|--------------|---------|----------------------|
| Bull     | Rapid supply chain normalization, strong sensor demand      | 1.10         | 0.27    | 57.5                 |
| Base     | Modest efficiency gains, steady demand, gradual inventory fix| 1.04         | 0.23    | 56.5                 |
| Bear     | Prolonged supply/inventory issues, regulatory headwinds     | 1.00         | 0.21    | 54.5                 |

**Most Likely:** The **Base case** is most probable, given management’s cautious guidance and persistent cost headwinds. Revenue growth will continue, but margin recovery will be gradual, not immediate.

## Appendix – Data Tables & Management Quotes

### Quarterly Revenue, EPS, and Margin Trends

| Quarter      | Revenue ($B) | EPS ($) | Gross Margin (%) | Operating Margin (%) |
|--------------|--------------|---------|------------------|----------------------|
| Q2 2023      | 0.910        | 0.28    | 61.0             | 19.2                 |
| Q3 2023      | 0.950        | 0.27    | 60.2             | 18.5                 |
| Q4 2023      | 1.010        | 0.25    | 58.7             | 17.0                 |
| Q1 2024      | 1.036        | 0.23    | 56.9             | 15.8                 |

### KPI Movement Table

| KPI                   | Q1 2023 | Q4 2023 | Q1 2024 | YoY Change | QoQ Change |
|-----------------------|---------|---------|---------|------------|------------|
| Sensor Revenue ($M)   | 720     | 850     | 842     | +17%       | –1%        |
| Net New Customers     | 120k    | 150k    | 155k    | +29%       | +3%        |
| Inventory Charges ($M)| 12.5    | 18.0    | 28.2    | +126%      | +57%       |

### Key Management Quotes

1. **“We continue to see strong demand and record new patient starts, particularly in the U.S.”**  
   Source: Q1 2024 Earnings Call  
   *Interpretation: Underpins confidence in top-line growth.*

2. **“Short-term margin pressures remain manageable as we address supply chain challenges.”**  
   Source: Q1 2024 Earnings Call  
   *Interpretation: Margin headwinds are expected to persist, but are not yet out of control.*

3. **“We are investing in manufacturing capacity to support future growth.”**  
   Source: Q1 2024 10-Q  
   *Interpretation: Capex will weigh on near-term cash flow, but is intended to drive long-term scale.*

4. **“We have initiated a $750 million share repurchase program.”**  
   Source: Q1 2024 Earnings Call  
   *Interpretation: Management is signaling confidence in long-term cash generation.*

5. **“We received an FDA warning letter related to quality systems at one facility.”**  
   Source: Q1 2024 10-Q  
   *Interpretation: Regulatory risk could impact production or costs if not resolved quickly.*

6. **“We expect full-year non-GAAP gross margin to be approximately 62%.”**  
   Source: Q1 2024 Earnings Call  
   *Interpretation: Implies some margin recovery is anticipated, but not imminent.*

7. **“Inventory adjustments and supply chain inefficiencies impacted Q1 margins.”**  
   Source: Q1 2024 Earnings Call  
   *Interpretation: Operational issues are a key near-term risk to profitability.*

---

**Conclusion:**  
DexCom’s next quarter will be defined by the **tension between strong sensor-driven growth and persistent margin headwinds**. Investors should closely monitor management’s commentary on supply chain normalization and regulatory developments for early signals of either upside or downside to the base case.

DexCom (DXCM): Growth Outpaces Margin Recovery